Recent implications of weight loss in lung cancer management

Nutrition

Volumn 12, Issue SUPPL.1, 1996, Pages

  Chlebowski, Rowan T ^a,b   Palomares, Melanie R ^a   Lillington, Linda ^a   Grosvenor, Mary ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Cancer associated weight loss; Lung cancer; Nutritional status

Indexed keywords

CORTICOSTEROID; CYPROHEPTADINE; DRONABINOL; GROWTH HORMONE; HYDRAZINE SULFATE; MEGESTROL ACETATE; PENTOXIFYLLINE;

ANTHROPOMETRY; CACHEXIA; CLINICAL TRIAL; CONFERENCE PAPER; DIETARY INTAKE; FATTY ACID METABOLISM; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; PARENTERAL NUTRITION; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL RATE; TUMOR GROWTH; WEIGHT REDUCTION;

CACHEXIA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PARENTERAL NUTRITION, TOTAL; RANDOMIZED CONTROLLED TRIALS; WEIGHT LOSS;

EID: 0029872949     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/0899-9007(95)00075-5     Document Type: Article

References (61)

1. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491
2. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213
3. Bass FB, Cox RH. The need for dietary counseling of cancer patients as indicated by nutrient and supplement intake. J Amer Diet Assoc 1995;95(11):1319
4. Chlebowski RT. Clinical trials of nutritional support in patients with cancer. In: Roche AF (ed.), Role of nutrients in cancer treatment. Columbus, OH:Ross Laboratories; 1991:74
5. Cancer Statistics, 1995: CA Cancer J Clin 1995;45:8
6. American College of Physicians. Position paper: Parenteral nutrition in patients receiving cancer chemotherapy. Ann Intern Med 1989;110:734
7. Jordan WM, Valdivieso M, Frankman C, et al. Treatment of advanced lung cancer with chemotherapy and intensive intravenous hyphalimentation. Cancer Treat Rep 1981;65:1997
8. Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small cell lung cancer. J Clin Oncol 1987;5:113
9. Grosvenor M, Bulcavage L, Chlebowski RT. Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer 1989;63:330
10. Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomized study. J Clin Oncol 1993;11:2043
11. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607
12. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657
13. Chlebowski RT, Bulcavage L, Grosvenor M, Oktay E, Block JB, Chlebowski JS, Ali I, Elashoff R. Influence of hydrazine sulfate on survival in non-small cell lung cancer. J Clinical Oncology 1990;8:9
14. Kosty MP, Fleishman SB, Herndon JE II, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994;12:1113
15. Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12:1126
16. Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12:1121
17. Tayek JA, Brasel JA. Failure of anabolism in malnourished cancer patients receiving growth hormone: A clinical research center study. J Clin Endocrinol Metab 1995;80(7):2082
18. Plasse TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695
19. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856
20. Tchekmedyian NS, Tait N, Moodly M, et al. High-dose megestrol acetate - A possible treatment for cachexia. JAMA 1987;257:1195
21. Loprinzi CI, Ellison NM, Schaid DJ, et al. A controlled trial of megestrol acetate in patients with cancer anorexia and/or cachexia. J Natl Cancer Inst 1990;82:1127
22. Parnes H, Conaway A, Kornblith MR, et al. A dose-response trial of megestrol acetate (MA) for the treatment of cachexia in patients with advanced cancer. Proc Amer Soc Clin Oncol 1994;13:451
23. Bruera E, Macmillan K, Kuehn N, et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279
24. Tchekmedyian NS, Hickman M, Heber D. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or AIDS. Semin Oncol 1991;18(Suppl 2):35
25. Feliv J, Gonzalaes-Baron M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia: A placebo controlled study. Am J Clin Oncol 1992;15(5):436:440
26. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11(4):762
27. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Bodycomposition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152
28. Kotler D. Effects of megestrol acetate on serum testosterone in AIDS. AIDS Conf 1994;10:PB0900
29. Rowland KM, Jett JR, Jung SH, Loprinzi CL, Washburn JH, Shaw EG. Phase III randomized double blind placebo controlled trial of cisplatin (P) and etoposide (E) plus megestrol acetate (M)/placebo in extensive stage small cell lung (SCLA): A North Central Cancer Treatment Group Study. Proc Amer Soc Clin Oncol 1994;13:330
30. Chlebowski RT, Grosvenor M, Bulcavage L. Glucose metabolism, nutritional status and prognosis in patients with non-small cell lung cancer. FASEB Proc 1991;5:3732
31. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1990:65:25
32. Graham MV, Geiz LM, Byhard R, et al. Comparison of prognostic factors and survival among black and white patients treated with radiation for non-small cell lung cancer. J Natl Cancer Inst 1992;84:1731
33. Ferguson MK, Skosey C, Hoffman PC, Golomb HM. Sex associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 1990;8:1402
34. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986;4:14
35. Paesmans M, Sculier JP, Libert P, Bureau G, et al. Prognostic factors for survival in advanced non-small cell lung cancer: Univariate and multivariate analyses including recurring partitioning and amalgamation algorithms in 1,052 patients. J Clin Oncol 1995;13:1221
36. Brown JK. Gender, age, usual weight and tobacco use as predictor of weight loss in patients with lung cancer. Oncol Nurs Forum 1993;20:466
37. Palomares MR, Lillington L, Shekar K, Grosvenor M, Sayre J, Chlebowski RT. Clinical outcome, gender, and weight loss in non-small cell lung cancer. Proc Amer Soc Clin Oncol 1996;14
38. Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to treatment. Cancer Res 1982;42:2495
39. Chiaavina YO, Tyutyunova AM, Chilingaryants SG. Correlation between the conditions of steroid balance and survival times in radically operated lung cancer patients. Vopr Onkol 1983;29:46
40. Recchione C, Galante E, Secreto G, et al. Abnormal serum hormone levels in lung cancer. Tumori 1983;69:293
41. Taggart DP, Gray CE, Bowman A, Faichney A, Davidson KG. Serum androgens and gonadotrophins in bronchial carcinoma. Respiratory Med 1993;87(6):455
42. Bols-Pratsch M, Yoan YD, Kenneth UA, Nieschlag E. Transdermal testosterone substitution therapy for male hypogonadism. Lancet 1986;II:943
43. Bhasin S: Androgen treatment of hypogonadal men. J Clin Endocrinol Metab 1992;74:1221
44. Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986;58:183
45. Hamalainen EK, Adlercrentz H, Puska P, Pietineir D. Decrease of serum total and free testosterone during a low-fat, high-fibre diet. Steroid Biochem 1983;18(3):369
46. Rose DP, Connolly JM, Liu XH. Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude nice, and their invasive capacity in vitro. Cancer Res 1994;54:6557
47. Chlebowski RT. Dietary fat and breast cancer: Low fat trials for protection. In: Stoll BA, ed. Reducing breast cancer risk in women. Kluwer Academic Publishers; 1995:109
48. Rose DP, Connolly JM. Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J Natl Cancer Inst 1993;85:1743
49. Hendrickse CW, Keighley MR, Neoptolemos JP. Dietary omega-3 fats reduce proliferation and tumor yields at colorectal anastomosis in rats. Gastroenterology 1995;109(2):431
50. Tisdale MJ, Beck SA, Hudson EA. Effects of eicosapentaenoic acid on tumor growth and cachexia in mouse colon cancer. Word Rev Nutr Diet 1994;76:86
51. Rose D, Connolly J. Effects of fatty acids and eicosanoid synthesis inhibitors in the growth of two human cancer cell lines. The Prostate 199;18:243
52. Purasiri P, Murray A, Richardson S, Heys SD, Horrobin D, Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci 1994;87(6):711
53. Anti M, Marra G, Armelao F, et al. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterology 1992;103:883
54. Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci 1994;87(6):711
55. Gardner TE, Lappin J, Daly JM. Immunologic enhancement with enteral fish oil supplementation in a cachectic tumor model. JPEN 1994;18(Suppl 1):18S
56. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899
57. Chlebowski RT, Lillington L. A decade of breast cancer clinical investigation: Results as reported in the Program Proceedings of the American Society of Clinical Oncology. J Clinical Oncology 1994;12:1789
58. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucorvorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:869
59. Van Triest B, Van Groeningin W, Penido HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 1995;31A(718):1193
60. Aaronsen NK, Ahmedzai S, Bergman B, et al. A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365
61. Kaplan RM, Feeny D, Revicki DA. Methods for assessing relative importance in preference based outcome measures. Quality of Life Res 1993;2:467